Risks and Benefits of Naltrexone
Naltrexone is an effective medication for both alcohol dependence and opioid use disorder prevention, reducing relapse risk by approximately 17% in alcohol dependence and maintaining abstinence in motivated opioid-dependent patients, but carries significant risks including hepatotoxicity and potentially life-threatening precipitated withdrawal in opioid-dependent individuals.
Benefits
For Alcohol Dependence
Naltrexone or acamprosate may be considered in combination with counseling to decrease the likelihood of relapse in patients with alcohol abuse/dependence who achieve abstinence 1. The evidence demonstrates:
- Reduces heavy drinking risk to 83% of placebo levels (RR 0.83,95% CI 0.76-0.90) 2
- Decreases drinking days by approximately 4% (MD -3.89,95% CI -5.75 to -2.04) 2
- Reduces heavy drinking days by 3.25 days (95% CI -5.51 to -0.99) 2
- Lowers total alcohol consumption and gamma-glutamyltransferase levels 2
- Works by blocking opioid receptors, thereby reducing alcohol cravings and the pleasurable "high" associated with drinking 1, 3
The Cochrane systematic review concluded that short-term naltrexone treatment lowers relapse risk 1. Treatment effects appear reliable when combined with counseling and psychosocial support 4.
For Opioid Use Disorder
Naltrexone has proven effective for opioid addiction treatment, particularly in motivated populations 5:
- Produces complete blockade of euphoric opioid effects 6
- Has very limited potential for misuse or diversion compared to opioid agonists 5
- Extended-release injectable formulation (380mg monthly) reduces adherence burden 3
- May be particularly useful for adolescents/young adults with co-occurring alcohol use disorder or those in unstable housing 5
- Most effective in motivated populations (e.g., healthcare professionals) who cannot or prefer not to use continuous opioid agonist therapy 3
Risks
Hepatotoxicity
Naltrexone has been shown to cause hepatocellular injury 1. The FDA label specifies 6:
- Cases of hepatitis and clinically significant liver dysfunction observed in clinical trials and postmarketing
- Transient, asymptomatic hepatic transaminase elevations documented
- Baseline liver function tests required, with monitoring every 3-6 months 3
- Should not be used in patients with acute hepatitis or liver failure 7
- Given potential hepatotoxicity, naltrexone has not been tested in patients with alcoholic liver disease and its use in this population is not recommended 7
Precipitated Opioid Withdrawal
This is the most dangerous risk and can be life-threatening 6:
- Withdrawal symptoms can appear within 5 minutes and last up to 48 hours 6
- May cause confusion, somnolence, visual hallucinations, and significant fluid losses requiring IV hydration 6
- Some cases severe enough to require ICU admission 6
- Patients must be opioid-free (including tramadol) for minimum 7-10 days before starting naltrexone 6
- Patients transitioning from buprenorphine or methadone may be vulnerable for up to 2 weeks 6
Critical pitfall: Precipitated withdrawal has occurred in alcohol-dependent patients when prescribers were unaware of concurrent opioid use 6. Always assess for underlying opioid dependence before initiating naltrexone in any patient.
Opioid Blockade Risks
- Any attempt to overcome the blockade by taking opioids is especially dangerous and may lead to life-threatening intoxication or fatal overdose 6
- Patients discontinuing naltrexone have decreased opioid tolerance, increasing overdose risk 3
- Naltrexone blocks therapeutic opioid effects for pain management, cough suppression, and diarrhea treatment 6
Other Adverse Effects
Common side effects include 2:
- Gastrointestinal problems, particularly nausea (10% increased risk)
- Sedative effects including daytime sleepiness (9% increased risk)
- Generally well-tolerated with few serious adverse events 6
Depression and Suicidality
Depression, suicide attempts, and suicidal ideation reported in postmarketing surveillance for opioid dependence treatment 6. Monitor all patients for emergence of depression or suicidal thinking; alert families and caregivers to watch for these symptoms 6.
Clinical Implementation
For alcohol dependence: Use 50mg daily combined with counseling 6. Most effective when part of comprehensive treatment including compliance-enhancing protocols 6.
For opioid dependence: Start with 25mg test dose; if no withdrawal, advance to 50mg daily 6. Only effective when given with external support ensuring medication compliance 6.
Contraindications: Active opioid use, acute hepatitis, liver failure, patients requiring opioid analgesics 7, 6.